{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:46:08Z","timestamp":1789976768243,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002456","name":"Chonnam National University","doi-asserted-by":"crossref","award":["HCRI 17907-1"],"award-info":[{"award-number":["HCRI 17907-1"]}],"id":[{"id":"10.13039\/501100002456","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002456","name":"Chonnam National University","doi-asserted-by":"crossref","award":["HCRI 17918-1"],"award-info":[{"award-number":["HCRI 17918-1"]}],"id":[{"id":"10.13039\/501100002456","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00432-019-02944-w","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:25:40Z","timestamp":1559431540000},"page":"2071-2082","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer"],"prefix":"10.1007","volume":"145","author":[{"given":"Cheol-Kyu","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Gun","family":"Kho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Ok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Joon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Joo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo-Duk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4837-1321","authenticated-orcid":false,"given":"In-Jae","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,1]]},"reference":[{"key":"2944_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jmoldx.2015.10.002","volume":"18","author":"C Beadling","year":"2016","unstructured":"Beadling C et al (2016) A multiplexed amplicon approach for detecting gene fusions by next-generation sequencing. J Mol Diagn 18:165\u2013175. \n                              https:\/\/doi.org\/10.1016\/j.jmoldx.2015.10.002","journal-title":"J Mol Diagn"},{"key":"2944_CR2","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.ccell.2015.09.018","volume":"28","author":"MG Best","year":"2015","unstructured":"Best MG et al (2015) RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 28:666\u2013676. \n                              https:\/\/doi.org\/10.1016\/j.ccell.2015.09.018","journal-title":"Cancer Cell"},{"key":"2944_CR3","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.18632\/oncotarget.13741","volume":"8","author":"S Cui","year":"2017","unstructured":"Cui S et al (2017) Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer Oncotarget 8:2771\u20132780. \n                              https:\/\/doi.org\/10.18632\/oncotarget.13741","journal-title":"Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer Oncotarget"},{"key":"2944_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.17.00160","volume":"2","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I et al (2018) Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA. JCO precision oncology 2:1\u20134. \n                              https:\/\/doi.org\/10.1200\/po.17.00160","journal-title":"JCO precision oncology"},{"key":"2944_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. \n                              https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2944_CR6","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","volume":"6","author":"JF Gainor","year":"2016","unstructured":"Gainor JF et al (2016) Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6:1118\u20131133. \n                              https:\/\/doi.org\/10.1158\/2159-8290.cd-16-0596","journal-title":"Cancer Discov"},{"key":"2944_CR7","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1200\/JCO.2017.74.6065","volume":"35","author":"N Hanna","year":"2017","unstructured":"Hanna N et al (2017) Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 35:3484\u20133515. \n                              https:\/\/doi.org\/10.1200\/jco.2017.74.6065","journal-title":"J Clin Oncol"},{"key":"2944_CR8","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1093\/annonc\/mds137","volume":"23","author":"M Ilie","year":"2012","unstructured":"Ilie M et al (2012) ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. Ann Oncol 23:2907\u20132913. \n                              https:\/\/doi.org\/10.1093\/annonc\/mds137","journal-title":"Ann Oncol"},{"key":"2944_CR9","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ccell.2015.10.007","volume":"28","author":"SA Joosse","year":"2015","unstructured":"Joosse SA, Pantel K (2015) Tumor-educated platelets as liquid biopsy in cancer patients. Cancer Cell 28:552\u2013554. \n                              https:\/\/doi.org\/10.1016\/j.ccell.2015.10.007","journal-title":"Cancer Cell"},{"issue":"Suppl 3","key":"2944_CR10","doi-asserted-by":"publisher","first-page":"iii16","DOI":"10.1093\/annonc\/mdw302","volume":"27","author":"KM Kerr","year":"2016","unstructured":"Kerr KM, Lopez-Rios F (2016) Precision medicine in NSCLC and pathology: how does ALK fit in the pathway? Ann Oncol 27(Suppl 3):iii16\u2013iii24. \n                              https:\/\/doi.org\/10.1093\/annonc\/mdw302","journal-title":"Ann Oncol"},{"key":"2944_CR11","doi-asserted-by":"publisher","first-page":"45399","DOI":"10.18632\/oncotarget.17535","volume":"8","author":"LL Li","year":"2017","unstructured":"Li LL et al (2017) Circulating microRNAs as novel biomarkers of ALK-positive nonsmall cell lung cancer and predictors of response to crizotinib therapy. Oncotarget 8:45399\u201345414. \n                              https:\/\/doi.org\/10.18632\/oncotarget.17535","journal-title":"Oncotarget"},{"key":"2944_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","volume":"7","author":"JJ Lin","year":"2017","unstructured":"Lin JJ, Riely GJ, Shaw AT (2017) Targeting ALK: precision medicine takes on drug resistance. Cancer Discov 7:137\u2013155. \n                              https:\/\/doi.org\/10.1158\/2159-8290.cd-16-1123","journal-title":"Cancer Discov"},{"key":"2944_CR13","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","volume":"36","author":"JJ Lin","year":"2018","unstructured":"Lin JJ et al (2018) Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer. J Clin Oncol 36:1199\u20131206. \n                              https:\/\/doi.org\/10.1200\/jco.2017.76.2294","journal-title":"J Clin Oncol"},{"key":"2944_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","volume":"13","author":"NI Lindeman","year":"2018","unstructured":"Lindeman NI et al (2018) Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline From the college of american pathologists, the international association for the study of lung cancer, and the association for molecular pathology. J Thorac Oncol 13:323\u2013358. \n                              https:\/\/doi.org\/10.1016\/j.jtho.2017.12.001","journal-title":"J Thorac Oncol"},{"key":"2944_CR15","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","volume":"36","author":"JD Merker","year":"2018","unstructured":"Merker JD et al (2018) Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol 36:1631\u20131641. \n                              https:\/\/doi.org\/10.1200\/JCO.2017.76.8671","journal-title":"J Clin Oncol"},{"key":"2944_CR16","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1182\/blood-2011-03-344408","volume":"118","author":"RJ Nilsson","year":"2011","unstructured":"Nilsson RJ et al (2011) Blood platelets contain tumor-derived RNA biomarkers. Blood 118:3680\u20133683. \n                              https:\/\/doi.org\/10.1182\/blood-2011-03-344408","journal-title":"Blood"},{"key":"2944_CR17","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.18632\/oncotarget.6279","volume":"7","author":"RJ Nilsson","year":"2016","unstructured":"Nilsson RJ et al (2016) Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. Oncotarget 7:1066\u20131075. \n                              https:\/\/doi.org\/10.18632\/oncotarget.6279","journal-title":"Oncotarget"},{"key":"2944_CR18","unstructured":"Non-small cell lung cancer (Version 6.2018) (2018) National comprehensive cancer network. \n                              http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"},{"key":"2944_CR19","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","volume":"29","author":"S Novello","year":"2018","unstructured":"Novello S et al (2018) Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol 29:1409\u20131416. \n                              https:\/\/doi.org\/10.1093\/annonc\/mdy121","journal-title":"Ann Oncol"},{"key":"2944_CR20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/JTO.0b013e31820b82e8","volume":"6","author":"JH Paik","year":"2011","unstructured":"Paik JH et al (2011) Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 6:466\u2013472. \n                              https:\/\/doi.org\/10.1097\/JTO.0b013e31820b82e8","journal-title":"J Thorac Oncol"},{"key":"2944_CR21","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1200\/JCO.2012.44.5932","volume":"31","author":"E Pailler","year":"2013","unstructured":"Pailler E et al (2013) Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol 31:2273\u20132281. \n                              https:\/\/doi.org\/10.1200\/jco.2012.44.5932","journal-title":"J Clin Oncol"},{"key":"2944_CR22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.21037\/tlcr.2016.10.07","volume":"5","author":"D Perez-Callejo","year":"2016","unstructured":"Perez-Callejo D, Romero A, Provencio M, Torrente M (2016) Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring Transl Lung. Cancer Res 5:455\u2013465. \n                              https:\/\/doi.org\/10.21037\/tlcr.2016.10.07","journal-title":"Cancer Res"},{"key":"2944_CR23","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S et al (2017) Alectinib versus crizotinib in untreated alk-positive non-small-cell lung cancer. N Engl J Med 377:829\u2013838. \n                              https:\/\/doi.org\/10.1056\/nejmoa1704795","journal-title":"N Engl J Med"},{"key":"2944_CR24","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D et al (2018) Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv192\u2013iv237. \n                              https:\/\/doi.org\/10.1093\/annonc\/mdy275","journal-title":"Ann Oncol"},{"key":"2944_CR25","doi-asserted-by":"publisher","first-page":"e20569","DOI":"10.1200\/JCO.2017.35.15_suppl.e20569","volume":"35","author":"C Rolfo","year":"2017","unstructured":"Rolfo C et al (2017) Liquid biopsy analysis of ALK alterations from advanced NSCLC patients: the value of exosomal RNA cargo (ExoALK). J Clin Oncol 35:e20569\u2013e20569. \n                              https:\/\/doi.org\/10.1200\/jco.2017.35.15_suppl.e20569","journal-title":"J Clin Oncol"},{"key":"2944_CR26","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","volume":"13","author":"C Rolfo","year":"2018","unstructured":"Rolfo C et al (2018) Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol 13:1248\u20131268. \n                              https:\/\/doi.org\/10.1016\/j.jtho.2018.05.030","journal-title":"J Thorac Oncol"},{"key":"2944_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3389\/fimmu.2015.00050","volume":"6","author":"M S\u00e1enz-Cuesta","year":"2015","unstructured":"S\u00e1enz-Cuesta M et al (2015) Methods for extracellular vesicles isolation in a hospital setting. Front Immunol 6:50. \n                              https:\/\/doi.org\/10.3389\/fimmu.2015.00050","journal-title":"Front Immunol"},{"key":"2944_CR28","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.ejca.2010.04.002","volume":"46","author":"T Sasaki","year":"2010","unstructured":"Sasaki T, Rodig SJ, Chirieac LR, Janne PA (2010) The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 46:1773\u20131780. \n                              https:\/\/doi.org\/10.1016\/j.ejca.2010.04.002","journal-title":"Eur J Cancer"},{"key":"2944_CR29","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","volume":"27","author":"AT Shaw","year":"2009","unstructured":"Shaw AT et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247\u20134253. \n                              https:\/\/doi.org\/10.1200\/jco.2009.22.6993","journal-title":"J Clin Oncol"},{"key":"2944_CR30","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385\u20132394. \n                              https:\/\/doi.org\/10.1056\/NEJMoa1214886","journal-title":"N Engl J Med"},{"key":"2944_CR31","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw AT et al (2017) Ceritinib versus chemotherapy in patients with ALK rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 18:874\u2013886. \n                              https:\/\/doi.org\/10.1016\/s1470-2045(17)30339-x","journal-title":"Lancet Oncol"},{"key":"2944_CR32","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561\u2013566. \n                              https:\/\/doi.org\/10.1038\/nature05945","journal-title":"Nature"},{"key":"2944_CR33","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167\u20132177. \n                              https:\/\/doi.org\/10.1056\/NEJMoa1408440","journal-title":"N Engl J Med"},{"key":"2944_CR34","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","volume":"36","author":"BJ Solomon","year":"2018","unstructured":"Solomon BJ et al (2018) Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin Oncol 36:2251\u20132258. \n                              https:\/\/doi.org\/10.1200\/jco.2017.77.4794","journal-title":"J Clin Oncol"},{"key":"2944_CR35","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","volume":"389","author":"J-C Soria","year":"2017","unstructured":"Soria J-C et al (2017) First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 389:917\u2013929. \n                              https:\/\/doi.org\/10.1016\/s0140-6736(17)30123-x","journal-title":"Lancet"},{"key":"2944_CR36","doi-asserted-by":"crossref","first-page":"65208","DOI":"10.18632\/oncotarget.11569","volume":"7","author":"Y Wang","year":"2016","unstructured":"Wang Y et al (2016) Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing. Oncotarget 7:65208\u201365217","journal-title":"Oncotarget"},{"key":"2944_CR37","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/annonc\/mdx673.003","volume":"28","author":"CG Woo","year":"2017","unstructured":"Woo CG et al (2017) Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Ann Oncol 28:791\u2013797. \n                              https:\/\/doi.org\/10.1093\/annonc\/mdw693","journal-title":"Ann Oncol"},{"key":"2944_CR38","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1158\/2159-8290.cd-17-1256","volume":"8","author":"S Yoda","year":"2018","unstructured":"Yoda S, Lin JJ (2018) Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive. Lung Cancer 8:714\u2013729. \n                              https:\/\/doi.org\/10.1158\/2159-8290.cd-17-1256","journal-title":"Lung Cancer"},{"key":"2944_CR39","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2015.65.8732","volume":"34","author":"T Yoshida","year":"2016","unstructured":"Yoshida T et al (2016) Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer. J Clin Oncol 34:3383\u20133389. \n                              https:\/\/doi.org\/10.1200\/jco.2015.65.8732","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-02944-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-019-02944-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-02944-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T23:07:54Z","timestamp":1590880074000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-019-02944-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["2944"],"URL":"https:\/\/doi.org\/10.1007\/s00432-019-02944-w","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]},"assertion":[{"value":"18 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data were gathered in accordance with the amended Declaration of Helsinki and following the approval of an independent Institutional Review Board (IRB) of the hospital (IRB approval number: CNUHH-2018-107).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consents were waived on account of the retrospective design of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Data supporting the conclusions of this article are included in the article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}}]}}